HopeHealth Launches Phase 3 Clinical Trial Site To Advance Lupus Research

HopeHealth announced last week that it is participating in a pivotal phase 3 clinical research study, sponsored by global pharmaceutical company Bristol Myers Squibb (BMS), to evaluate an investigational treatment in patients with systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease in which the immune system attacks healthy tissues, often causing inflammation, pain, and organ damage.

This marks the first clinical trial hosted by HopeHealth, a significant milestone in its efforts to expand local research capacity. The clinical study in which HopeHealth is participating is also an important advancement to improve potential future treatment options among the local population for SLE, which disproportionately impacts medically underserved communities. HopeHealth’s clinical trial site is operational, and they have successfully enrolled patients in the trial.

To read the full press release, click here.